SCHEMBL5648564

SCHEMBL5648564

COc1ccccc1-c1ccn(OC(=O)N2CCOCC2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
SMN1; SMN2 Q16637 3/20 0.48
HPGD P15428 3/20 0.48
MAPT P10636 2/20 0.48
ALDH1A1 P00352 1/20 0.48
HTT P42858 1/20 0.48
TP53 P04637 2/20 0.48
TSHR P16473 2/20 0.47
CNR2 P34972 1/20 0.47
AKR1C3 P42330 1/20 0.46
KDM4E B2RXH2 3/20 0.45
PIK3CD O00329 2/20 0.43
PIK3R2 O00459 2/20 0.43
PIK3CA P42336 2/20 0.43
PIK3CB P42338 2/20 0.43
PIK3CG P48736 2/20 0.43
PIK3R5 Q8WYR1 2/20 0.43
PIK3R3 Q92569 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650420 0.88 HPGD (0.48) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL5653508 0.84 TP53 (0.44) NPC1RAB9ASMN1; SMN2HPGDTP53
SCHEMBL5648446 0.82 GAA (0.49) SMN1; SMN2HPGDMAPTALDH1A1TSHR
SCHEMBL5647676 0.79 TP53 (0.49) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL5652053 0.78 TP53 (0.45) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL5648637 0.74 NPC1 (0.48) NPC1RAB9ATDP1SMN1; SMN2HPGD
SCHEMBL5648683 0.72 TP53 (0.45) NPC1RAB9ASMN1; SMN2MAPTHTT
SCHEMBL5646616 0.72 L3MBTL1 (0.41) MAPTALDH1A1TP53KDM4ELMNA
SCHEMBL27564850 0.72 AR (0.43) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL5650297 0.71 NPC1 (0.45) NPC1RAB9ASMN1; SMN2HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP claimed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US claimed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO claimed
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL NPC1 814/4885RAB9A 2926/4885TDP1 1935/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL NPC1 973/4885RAB9A 3386/4885TDP1 1957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.